267 related articles for article (PubMed ID: 31840740)
1. Predictive factors for the outcomes of Graves' disease patients with radioactive iodine (131I) treatment.
Xing YZ; Zhang K; Jin G
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31840740
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors of outcomes in personalized radioactive iodine ((131)I) treatment for Graves' disease.
Liu M; Jing D; Hu J; Yin S
Am J Med Sci; 2014 Oct; 348(4):288-93. PubMed ID: 24805788
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.
Hu RT; Liu DS; Li B
BMC Endocr Disord; 2020 May; 20(1):76. PubMed ID: 32471411
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease.
Moura-Neto A; Mosci C; Santos AO; Amorim BJ; de Lima MC; Etchebehere EC; Tambascia MA; Ramos CD; Zantut-Wittmann DE
Clin Nucl Med; 2012 Jun; 37(6):550-4. PubMed ID: 22614185
[TBL] [Abstract][Full Text] [Related]
5. Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy.
Yu F; Zhang R; Zhang G; Meng Z; Liu X; He Y; Tan J; Wang R
Med Sci Monit; 2021 Jan; 27():e928796. PubMed ID: 33497370
[TBL] [Abstract][Full Text] [Related]
6. Effect of Lugol's solution on
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Clin Exp Med; 2023 Jul; 23(3):825-831. PubMed ID: 35840869
[TBL] [Abstract][Full Text] [Related]
7. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
[TBL] [Abstract][Full Text] [Related]
8. Correlation of radioiodine doses for 6-hr and 24-hour iodine-131 thyroid uptake values for Graves' hyperthyroidism.
Horn-Lodewyk J
Endocr J; 2019 Dec; 66(12):1047-1052. PubMed ID: 31391354
[TBL] [Abstract][Full Text] [Related]
9. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of (99m)Tc-pertechnetate thyroid scintigraphy in radioiodine therapy in a cohort of Chinese Graves' disease patients: a pilot clinical study.
Hou H; Hu S; Fan R; Sun W; Zhang X; Tian M
Biomed Res Int; 2015; 2015():974689. PubMed ID: 25879041
[TBL] [Abstract][Full Text] [Related]
11. Thyroid volume is the key predictor of hyperthyroidism remission after radioactive iodine therapy in pediatric patients.
Sheremeta M; Korchagina M; Trukhin A; Nagaeva E; Bezlepkina O; Peterkova V
Eur J Pediatr; 2023 Nov; 182(11):4931-4937. PubMed ID: 37606704
[TBL] [Abstract][Full Text] [Related]
12. The effect of short-term treatment with lithium carbonate on the outcome of radioiodine therapy in patients with long-lasting Graves' hyperthyroidism.
Sekulić V; Rajić M; Vlajković M; Ilić S; Stević M; Kojić M
Ann Nucl Med; 2017 Dec; 31(10):744-751. PubMed ID: 28895066
[TBL] [Abstract][Full Text] [Related]
13. [Predictors of the efficacy of radioiodine therapy of Graves' disease in children and adolescents].
Rumyantsev PO; Saenko VA; Dzeytova DS; Trukhin AA; Sheremeta MS; Slashchuk KY; Degtyarev MV; Serzhenko SS; Yasuchenia VS; Zakharova SM; Sirota YI
Probl Endokrinol (Mosk); 2020 Oct; 66(4):68-76. PubMed ID: 33351361
[TBL] [Abstract][Full Text] [Related]
14. Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India.
Sankar R; Sekhri T; Sripathy G; Walia RP; Jain SK
J Assoc Physicians India; 2005 Jul; 53():603-6. PubMed ID: 16190128
[TBL] [Abstract][Full Text] [Related]
15. Strategies of radioiodine therapy for Graves' disease.
Lind P
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S453-7. PubMed ID: 12192545
[TBL] [Abstract][Full Text] [Related]
16. The predictive role of 24h RAIU with respect to the outcome of low fixed dose radioiodine therapy in patients with diffuse toxic goiter.
Damle N; Bal C; Kumar P; Reddy R; Virkar D
Hormones (Athens); 2012; 11(4):451-7. PubMed ID: 23422768
[TBL] [Abstract][Full Text] [Related]
17. Painless thyroiditis mimicking relapse of hyperthyroidism during or after potassium iodide or thionamide therapy for Graves' disease resulting in remission.
Okamura K; Sato K; Fujikawa M; Bandai S; Ikenoue H; Kitazono T
Endocr J; 2023 Feb; 70(2):207-222. PubMed ID: 36351595
[TBL] [Abstract][Full Text] [Related]
18. The influence of non-radioactive iodine (127I) on the outcome of radioiodine (131I) therapy in patients with Graves' disease and toxic nodular goitre.
Rogowski F; Abdelrazek S; Szumowski P; Zonenberg A; Parfienczyk A; Sawicka A
Nucl Med Rev Cent East Eur; 2011; 14(1):9-15. PubMed ID: 21751166
[TBL] [Abstract][Full Text] [Related]
19.
Zhao L; Zhang W; Xin Y; Wen Q; Bail L; Guan F; Bin J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(6):349-353. PubMed ID: 30413358
[TBL] [Abstract][Full Text] [Related]
20. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
